# Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome

> **NCT01163643** · PHASE2 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 356 (actual)

## Conditions studied

- Dry Eye Syndrome

## Interventions

- **DRUG:** 0.3% BOL-303242-X ophthalmic suspension
- **DRUG:** 2% BOL-303242-X ophthalmic suspension
- **DRUG:** Placebo Comparator: Vehicle
- **DRUG:** 1% BOL-303242-X ophthalmic suspension
- **DRUG:** 2% BOL-303242-X ophthalmic suspension AM
- **DRUG:** 2% BOL-303242-X ophthalmic suspension PM

## Key facts

- **NCT ID:** NCT01163643
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-06
- **Final completion:** 2011-07
- **Target enrollment:** 356 (ACTUAL)
- **Last updated:** 2020-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01163643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01163643, "Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01163643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*